Roche Expects Sales, Earnings Growth
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...
The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...
Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...
After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...
Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles she has held at Zoetis and at Eli Lilly.
The upscale French furniture-maker posted preliminary revenues of 414 million euros for the full year, but said its fourth ...
Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF290.00.
So get your questions in now for Art and he will be with you between 4pm and 5pm GMT (11am to 12pm ET) to answer as many as he can ...
Two Massachusetts men were indicted for COVID-19 fraud, facing charges of wire fraud conspiracy and wire fraud after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback